Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;37(4):468-474.
doi: 10.5114/ada.2019.83983. Epub 2019 Jul 25.

Non-alcoholic fatty liver disease in patients with psoriasis: therapeutic implications

Elzbieta H Klujszo  1 , Piotr Parcheta  1 , Anna B Witkowska  2 , Beata Krecisz  3
Affiliations
Review

Non-alcoholic fatty liver disease in patients with psoriasis: therapeutic implications

Elzbieta H Klujszo et al. Postepy Dermatol Alergol. 2020 Aug.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common liver pathology in the western countries. Psoriatic patients are at higher risk of having NAFLD, and at higher risk of experiencing a more severe form of the disease with poorer outcomes. The components of the metabolic syndrome - obesity, lipid abnormalities, hypertension, and type 2 diabetes - significantly correlate with NAFLD progression. The inflammatory state present in psoriasis plays a significant role in development of NAFLD and the metabolic syndrome. All patients with psoriasis and insulin resistance and risk factors for metabolic syndrome should also been screened for NAFLD, and planning of the treatment options should always take into consideration the possible risks related to the liver, especially in patients with NAFLD.

Keywords: biologic agents; liver disease; methotrexate; psoriasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Hypothesized connections between the skin, adipose tissue (WAT) and liver damage – a “vicious circle”. Modified from Mantovani et al. [33] TNF – tumour necrosis factor, CRP – C-reactive protein, IL-6 – interleukin 6, IL-17 – interleukin 17, NAFLD – non-alcoholic fatty liver disease, NASH – non-alcoholic steatohepatitis.
See this image and copyright information in PMC

References

    1. Di Meglio P, Nestle FO. Immunopathogenesis of Psoriasis. In: Gaspari A, Tyring S, Kaplan D, editors. Clinical and Basic Immunodermatology. Cham: Springer; 2017.
    1. Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130:1785–96. - PubMed
    1. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: implications for management. J Am Acad Dermatol. 2017;76:393–403. - PMC - PubMed
    1. Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149:1173–9. - PMC - PubMed
    1. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68:654–62. - PubMed